A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study

BACKGROUND: We report a case of neuromyelitis optica spectrum disorders (NMOSD), who developed after the pembrolizumab treatment, an immune checkpoint inhibitor, against lung adenocarcinoma. The present case is discussed with the lung adenocarcinoma specimen which was stained by aquaporin-4 (AQP4) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirano, Shigeki, Kojima, Akira, Nakayama, Yoko, Takeda, Takahiro, Kishimoto, Takashi, Takahashi, Toshiyuki, Kuwabara, Satoshi, Mori, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753385/
https://www.ncbi.nlm.nih.gov/pubmed/36517738
http://dx.doi.org/10.1186/s12883-022-02987-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753385/
https://www.ncbi.nlm.nih.gov/pubmed/36517738
http://dx.doi.org/10.1186/s12883-022-02987-6

Ejemplares similares